Search

Your search keyword '"Zielinski C"' showing total 1,458 results
Start Over Author "Zielinski C"
1,458 results on '"Zielinski C"'

203. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia

Author

Heller, G, primary, Topakian, T, additional, Altenberger, C, additional, Cerny-Reiterer, S, additional, Herndlhofer, S, additional, Ziegler, B, additional, Datlinger, P, additional, Byrgazov, K, additional, Bock, C, additional, Mannhalter, C, additional, Hörmann, G, additional, Sperr, W R, additional, Lion, T, additional, Zielinski, C C, additional, Valent, P, additional, and Zöchbauer-Müller, S, additional

Published
2016
Full Text
View/download PDF

206. Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Author

Vrdoljak, E, primary, Marschner, N, additional, Zielinski, C, additional, Gligorov, J, additional, Cortes, J, additional, Puglisi, F, additional, Aapro, M, additional, Fallowfield, L, additional, Fontana, A, additional, Inbar, M, additional, Kahan, Z, additional, Welt, A, additional, Lévy, C, additional, Brain, E, additional, Pivot, X, additional, Putzu, C, additional, Gonzalez-Martin, A, additional, Ebel, K, additional, Easton, V, additional, and von Minckwitz, G, additional

Published
2016
Full Text
View/download PDF

212. TANIA: A randomized phase III trial evaluating continued and reintroduced bevacizumab in patients previously treated with first-line bevacizumab for locally recurrent/metastatic breast cancer

Author

von Minckwitz, G, Cortes, J, Gligorov, J, Marschner, N, Puglisi, F, Vrdoljak, e, Duenne, A, and Zielinski, C

Subjects
genetic structures, sense organs, metastatic breast cancer, eye diseases
Abstract

A randomized phase III trial evaluating continued and reintroduced bevacizumab in patients previously treated with first-line bevacizumab for locally recurrent/metastatic breast cancer

Published
2012

216. Abstract P3-06-10: Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial

Author

Christoph, Zielinski C, primary, Istvan, Lang, additional, Semir, Beslija, additional, Zsuzsanna, Kahan, additional, Inbar, Moshe J, additional, Salomon, Stemmer M, additional, Rodica, Anghel, additional, Damir, Vrbanec, additional, Diethelm, Messinger, additional, and Thomas, Brodowicz, additional

Published
2015
Full Text
View/download PDF

218. The potential of continuous near-field recording of infrasound produced by volcanoes in Vanuatu for probing the the state of the atmosphere

Author

Zielinski, C., Vergnolle, S., Bani, P., BUNC, Pole ID, Pôle Pluridisciplinaire de la Matière et de l'Environnement (PPME), and Université de la Nouvelle-Calédonie (UNC)

Subjects
[SDU.STU.VO] Sciences of the Universe [physics]/Earth Sciences/Volcanology, [SDU.STU.VO]Sciences of the Universe [physics]/Earth Sciences/Volcanology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

220. Multiyear validation of the NRL-G2S wind fields using infrasound from Yasur - art. no. D23110

Author

Antier, K., Le Pichon, A., Vergniolle, S., Zielinski, C., and Lardy, Michel

Abstract

The Yasur volcano in the Vanuatu archipelago is an outstanding source of infrasonic waves due to its regular activity. This volcano is permanently monitored by the IS22 infrasound station located in New Caledonia, about 400 km from it, and by one microbarometer installed close to its crater. A multiyear monitoring of Yasur is proposed to validate consistently the Naval Research Laboratory Ground to Space (NRL-G2S) semiempirical atmospheric model up to the stratosphere. The results of propagation modeling accurately explain seasonal changes as well as small short-timescale variations of the infrasonic observables. The azimuthal deviation is predicted with an uncertainty in general lower than 0.5 degrees. The fluctuations of the trace velocity and the celerity are simulated with errors as large as 5 m/s. This study demonstrates that the use of appropriate propagation tools along with the NRL-G2S specifications provides accurate enough results for most of the long-range observations for the purpose of operational infrasound monitoring.

Published
2007

223. Onkologie

Author

Marosi, C., primary, Vutuc, C., additional, Greinix, H. T., additional, Dörner-Fazeny, B., additional, and Zielinski, C., additional

Full Text
View/download PDF

224. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Author

Brodowicz, T, primary, Lang, I, additional, Kahan, Z, additional, Greil, R, additional, Beslija, S, additional, Stemmer, S M, additional, Kaufman, B, additional, Petruzelka, L, additional, Eniu, A, additional, Anghel, R, additional, Koynov, K, additional, Vrbanec, D, additional, Pienkowski, T, additional, Melichar, B, additional, Spanik, S, additional, Ahlers, S, additional, Messinger, D, additional, Inbar, M J, additional, and Zielinski, C, additional

Published
2014
Full Text
View/download PDF

225. Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases

Author

Bartsch, R., primary, Berghoff, A.S., additional, Vogl, U., additional, Rudas, M., additional, Bergen, E., additional, Gnant, M., additional, Dieckmann, K., additional, Pinker-Domenig, K., additional, Oehler, L., additional, Zielinski, C., additional, Steger, G.G., additional, and Preusser, M., additional

Published
2014
Full Text
View/download PDF

227. Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsai): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006)

Author

Martin, M., primary, Beslija, S., additional, Carrasco, E., additional, Kahan, Z., additional, Escudero, M.J., additional, Láng, I., additional, Bartlett, C.H., additional, Bermejo, B., additional, Inbar, M., additional, Chacón, J.I., additional, Jinga, D.C., additional, García-Sáenz, J.A., additional, De Haba, J.La, additional, Koehler, M., additional, Morales, S., additional, Gil, J.M., additional, Antón, A., additional, Ruiz-Borrego, M., additional, Murillo, L., additional, and Zielinski, C., additional

Published
2014
Full Text
View/download PDF

228. Efficacy and Safety in Tania, a Randomised Phase III Trial of Continued or Reintroduced Bevacizumab (Bev) After 1St-Line Bev for Her2-Negative Locally Recurrent/Metastatic Breast Cancer (Lr/Mbc)

Author

von Minckwitz, G., primary, Puglisi, F., additional, Cortes, J., additional, Vrdoljak, E., additional, Marschner, N., additional, Zielinski, C., additional, Villanueva, C.B., additional, Romieu, G., additional, Láng, I., additional, Ciruelos, E., additional, De Laurentiis, M., additional, Veyret, C., additional, De Ducla, S., additional, Freudensprung, U., additional, Srock, S., additional, and Gligorov, J., additional

Published
2014
Full Text
View/download PDF

237. TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine

Author

Pascual-Reguant, A, Bayat Sarmadi, J, Baumann, C, Noster, R, Cirera-Salinas, D, Curato, C, Pelczar, P, Huber, S, Zielinski, C E, Löhning, M, Hauser, A E, and Esplugues, E

Abstract

TH17 cells are major drivers of inflammation and involved in several autoimmune diseases. Tissue inflammation is a beneficial host response to infection, but it can also contribute to autoimmunity. The crosstalk between a tissue and the immune system during an inflammatory response is key for preserving tissue integrity and restoring physiological processes. However, how the inflamed tissue regulates the magnitude of an immune response by controlling pro-inflammatory T cells is not well characterized so far. Here we show that TH17 cells accumulating in the small intestine upon inflammation express the IL-33 receptor (ST2) and intestinal epithelial cells (IEC) are the main source of the alarmin interleukin-33 (IL-33). We show that pro-inflammatory TH17 cells acquire a regulatory phenotype with immunosuppressive properties in response to IL-33. Absence of ST2 signaling promotes the secretion of pro-inflammatory cytokines by TH17 cells and dampens the secretion of IL-10. Our results provide new insights into the mechanisms by which IEC, via IL-33/ST2 axis, may control pro-inflammatory TH17 cells in the small intestine to sustain homeostasis.

Published
2017
Full Text
View/download PDF

238. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Author

Brodowicz, T, primary, Pienkowski, T, additional, Beslija, S, additional, Melichar, B, additional, Lang, I, additional, Inbar, MJ, additional, Anghel, R, additional, Spanik, S, additional, Ahlers, S, additional, and Zielinski, C, additional

Published
2013
Full Text
View/download PDF

239. MEDICAL RADIATION THERAPIES

Author

Ahmed, I., primary, Biswas, A., additional, Krishnamurthy, S., additional, Julka, P., additional, Rath, G., additional, Back, M., additional, Huang, D., additional, Gzell, C., additional, Chen, J., additional, Kastelan, M., additional, Gaur, P., additional, Wheeler, H., additional, Badiyan, S. N., additional, Robinson, C. G., additional, Simpson, J. R., additional, Tran, D. D., additional, Rich, K. M., additional, Dowling, J. L., additional, Chicoine, M. R., additional, Leuthardt, E. C., additional, Kim, A. H., additional, Huang, J., additional, Michaelsen, S. R., additional, Christensen, I. J., additional, Grunnet, K., additional, Stockhausen, M.-T., additional, Broholm, H., additional, Kosteljanetz, M., additional, Poulsen, H. S., additional, Tieu, M., additional, Lovblom, E., additional, Macnamara, M., additional, Mason, W., additional, Rodin, D., additional, Tai, E., additional, Ubhi, K., additional, Laperriere, N., additional, Millar, B.-A., additional, Menard, C., additional, Perkins, B., additional, Chung, C., additional, Clarke, J., additional, Molinaro, A., additional, Phillips, J., additional, Butowski, N., additional, Chang, S., additional, Perry, A., additional, Costello, J., additional, DeSilva, A., additional, Rabbitt, J., additional, Prados, M., additional, Cohen, A. L., additional, Anker, C., additional, Shrieve, D., additional, Hall, B., additional, Salzman, K., additional, Jensen, R., additional, Colman, H., additional, Farber, O., additional, Weinberg, U., additional, Palti, Y., additional, Fisher, B., additional, Chen, H., additional, Macdonald, D., additional, Lesser, G., additional, Coons, S., additional, Brachman, D., additional, Ryu, S., additional, Werner-Wasik, M., additional, Bahary, J.-P., additional, Chakravarti, A., additional, Mehta, M., additional, Gupta, T., additional, Nair, V., additional, Epari, S., additional, Godasastri, J., additional, Moiyadi, A., additional, Shetty, P., additional, Juvekar, S., additional, Jalali, R., additional, Herrlinger, U., additional, Schafer, N., additional, Steinbach, J., additional, Weyerbrock, A., additional, Hau, P., additional, Goldbrunner, R., additional, Kohnen, R., additional, Urbach, H., additional, Stummer, W., additional, Glas, M., additional, Houillier, C., additional, Ghesquieres, H., additional, Chabrot, C., additional, Soussain, C., additional, Ahle, G., additional, Choquet, S., additional, Faurie, P., additional, Bay, J.-O., additional, Vargaftig, J., additional, Gaultier, C., additional, Nicolas-Virelizier, E., additional, Hoang-Xuan, K., additional, Iskanderani, O., additional, Izar, F., additional, Benouaich-Amiel, A., additional, Filleron, T., additional, Moyal, E., additional, Iweha, C., additional, Jain, S., additional, Melian, E., additional, Sethi, A., additional, Albain, K., additional, Shafer, D., additional, Emami, B., additional, Kong, X.-T., additional, Green, S., additional, Filka, E., additional, Green, R., additional, Yong, W., additional, Nghiemphu, P., additional, Cloughesy, T., additional, Lai, A., additional, Mallick, S., additional, Roy, S., additional, Purkait, S., additional, Gupta, S., additional, Julka, P. K., additional, Rath, G. K., additional, Marosi, C., additional, Thaler, J., additional, Ay, C., additional, Kaider, A., additional, Reitter, E.-M., additional, Haselbock, J., additional, Preusser, M., additional, Flechl, B., additional, Zielinski, C., additional, Pabinger, I., additional, Miyatake, S.-I., additional, Furuse, M., additional, Miyata, T., additional, Yoritsune, E., additional, Kawabata, S., additional, Kuroiwa, T., additional, Muragaki, Y., additional, Maruyama, T., additional, Iseki, H., additional, Akimoto, J., additional, Ikuta, S., additional, Nitta, M., additional, Maebayashi, K., additional, Saito, T., additional, Okada, Y., additional, Kaneko, S., additional, Matsumura, A., additional, Karasawa, K., additional, Nakazato, Y., additional, Kayama, T., additional, Nabors, L. B., additional, Fink, K. L., additional, Mikkelsen, T., additional, Grujicic, D., additional, Tarnawski, R., additional, Nam, D.-H., additional, Mazurkiewicz, M., additional, Salacz, M., additional, Ashby, L., additional, Thurzo, L., additional, Zagonel, V., additional, Depenni, R., additional, Perry, J. R., additional, Henslee-Downey, J., additional, Picard, M., additional, Reardon, D. A., additional, Nambudiri, N., additional, Nayak, L., additional, LaFrankie, D., additional, Wen, P., additional, Ney, D., additional, Carlson, J., additional, Damek, D., additional, Blatchford, P., additional, Gaspar, L., additional, Kavanagh, B., additional, Waziri, A., additional, Lillehei, K., additional, Reddy, K., additional, Chen, C., additional, Rashed, I., additional, Barton, K., additional, Anderson, D., additional, Prabhu, V., additional, Rusch, R., additional, Belongia, M., additional, Maheshwari, M., additional, Firat, S., additional, Schiff, D., additional, Desjardins, A., additional, Glantz, M., additional, Chamberlain, M., additional, Shapiro, W., additional, Gopal, S., additional, Judy, K., additional, Patel, S., additional, Mahapatra, A., additional, Shan, J., additional, Gupta, D., additional, Shih, K., additional, Bacha, J. A., additional, Brown, D., additional, Garner, W. J., additional, Steino, A., additional, Schwart, R., additional, Kanekal, S., additional, Li, M., additional, Lopez, L., additional, Burris, H. A., additional, Soderberg-Naucler, C., additional, Rahbar, A., additional, Stragliotto, G., additional, Song, A. J., additional, Kumar, A. M. S., additional, Murphy, E. S., additional, Tekautz, T., additional, Suh, J. H., additional, Recinos, V., additional, Chao, S. T., additional, Spoor, J., additional, Korami, K., additional, Kloezeman, J., additional, Balvers, R., additional, Dirven, C., additional, Lamfers, M., additional, Leenstra, S., additional, Sumrall, A., additional, Haggstrom, D., additional, Crimaldi, A., additional, Symanowski, J., additional, Giglio, P., additional, Asher, A., additional, Burri, S., additional, Sunkersett, G., additional, Khatib, Z., additional, Prajapati, C. M., additional, Magalona, E. E., additional, Mariano, M., additional, Sih, I. M., additional, Torcuator, R., additional, Taal, W., additional, Oosterkamp, H., additional, Walenkamp, A., additional, Beerenpoot, L., additional, Hanse, M., additional, Buter, J., additional, Honkoop, A., additional, Boerman, D., additional, de Vos, F., additional, Jansen, R., additional, van der Berkmortel, F., additional, Brandsma, D., additional, Enting, R., additional, Kros, J., additional, Bromberg, J., additional, van Heuvel, I., additional, Smits, M., additional, van der Holt, R., additional, Vernhout, R., additional, van den Bent, M., additional, Wick, W., additional, Suarez, C., additional, Rodon, J., additional, Forsyth, P., additional, Gueorguieva, I., additional, Cleverly, A., additional, Burkholder, T., additional, Desaiah, D., additional, Lahn, M., additional, Zach, L., additional, Guez, D., additional, Last, D., additional, Daniels, D., additional, Nissim, O., additional, Grober, Y., additional, Hoffmann, C., additional, Nass, D., additional, Talianski, A., additional, Spiegelmann, R., additional, Cohen, Z., additional, and Mardor, Y., additional

Published
2013
Full Text
View/download PDF

241. Crucial Issues For The Industrial Implementation of Porous Silicon

Author

Renat Bilyalov, Stalmans, Lieven, Matic, Zdeslav, Poortmans, Jef, Nijs, Johan, Bastide, S., Guillet, J., Lévy-Clément, C., Zielinski, C., Kübelbeck, A., Born, J., Schomann, F., Schum, B., and Schmidt, W.

Subjects
porous silicon, implementation, silicon
Abstract

Crucial issues for the implementation of porous silicon in industrial silicon solar cell process are considered from different viewpoints. Besides the intrinsic potential of porous Si as an alternative anti-reflection coating, the compatibility of the porous Si formation with screenprinted contacts on the one hand, and the cost aspect of the porous etching process on the other hand have been identified as the primary decision points. Three original concepts to limit the contact degradation and related fill factor decrease during porous silicon formation are specified and thoroughly discussed.

Published
2000

242. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations

Author

Wagner, T. M. U., Hirtenlehner, K., Shen, P., Moeslinger, R., Muhr, D., Fleischmann, E., Concin, H., Doeller, W., Haid, A., Lang, A. H., Mayer, P., Petru, E., Ropp, E., Langbauer, G., Kubista, E., Scheiner, O., Underhill, P., Mountain, J., Stierer, M., Zielinski, C., and Oefner, P.

Subjects
BRCA2 Protein, Male, Ovarian Neoplasms, Base Sequence, DNA Mutational Analysis, Genetic Variation, Breast Neoplasms, Neoplasm Proteins, Pedigree, Gene Frequency, Africa, Mutation, Humans, Female, Genes, Tumor Suppressor, DNA Primers, Transcription Factors
Abstract

The aim of this study was to evaluate the prevalence of simple sequence variation in the BRCA2 gene. To this end, 71 breast and breast-ovarian cancer (HBC/HBOC) families along with 95 control individuals from a wide range of ethnicities were analyzed by means of denaturing high-performance liquid chromatography (DHPLC) and direct sequence analysis. In the coding (10 257 bp) and non-coding (2799 bp) sequences of BRCA2, 82 sequence variants were identified. Three different, apparently disease-associated BRCA2 mutations were found in six HBC/HBOC families (8%): two splice site mutations in introns 5 and 21, and one frameshift mutation in exon 11. In the coding region, 53 simple sequence variants were found: 35 missense mutations, one 2 bp deletion (CT) resulting in a stop at codon 3364, one nonsense mutation with a stop at codon 3326, one deletion of a complete codon (AAA) resulting in the loss of leucine, and 15 silent mutations. In the non-coding region, 26 polymorphisms were detected. Of the 79 sequence variants that were not obviously disease-associated, eight were detected only in HBC/HBOC families. The remaining 71 variants were identified in both HBC/HBOC families and control individuals. Sixty three sequence variants (80%) were specific for a continent. Forty two percent (33 out of 79) of the sequence variants were detected exclusively in Africa, though only 13% of the 332 chromosomes screened were of African origin. Our data indicate that, in BRCA2, simple sequence variation is frequent [in the coding region 1 in 194 bp (straight theta = 2.2 x 10(-4)), and in the non-coding region 1 in 108 bp (straight theta = 4.4 x 10(-4)), respectively].

Published
1999

245. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Author

Lang, I., primary, Inbar, M.J., additional, Kahán, Z., additional, Greil, R., additional, Beslija, S., additional, Stemmer, S.M., additional, Kaufman, B., additional, Zvirbule, Z., additional, Steger, G.G., additional, Messinger, D., additional, Brodowicz, T., additional, and Zielinski, C., additional

Published
2012
Full Text
View/download PDF

246. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

Author

Berghoff, A S, primary, Bago-Horvath, Z, additional, Ilhan-Mutlu, A, additional, Magerle, M, additional, Dieckmann, K, additional, Marosi, C, additional, Birner, P, additional, Widhalm, G, additional, Steger, G G, additional, Zielinski, C C, additional, Bartsch, R, additional, and Preusser, M, additional

Published
2012
Full Text
View/download PDF

248. First Efficacy Results From the Turandot Phase III Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC)

Author

Zielinski, C., primary, Lang, I., additional, Inbar, M., additional, Kahan, Z., additional, Greil, R., additional, Beslija, S., additional, Stemmer, S.M., additional, Kaufman, B., additional, Zvirbule, Z., additional, Steger, G., additional, Melichar, B., additional, Pienkowski, T., additional, Sirbu, D., additional, Petruzelka, L., additional, Eniu, A., additional, Nisenbaum, B., additional, Dank, M., additional, Anghel, R., additional, Messinger, D., additional, and Brodowicz, T., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results